GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (FRA:BO1) » Definitions » Days Sales Outstanding

BioCryst Pharmaceuticals (FRA:BO1) Days Sales Outstanding : 57.72 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Days Sales Outstanding?

BioCryst Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2024 was €54.0 Mil. BioCryst Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €85.3 Mil. Hence, BioCryst Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 57.72.

The historical rank and industry rank for BioCryst Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

FRA:BO1' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.19   Med: 95.4   Max: 315.49
Current: 57

During the past 13 years, BioCryst Pharmaceuticals's highest Days Sales Outstanding was 315.49. The lowest was 44.19. And the median was 95.40.

FRA:BO1's Days Sales Outstanding is ranked better than
63.49% of 893 companies
in the Biotechnology industry
Industry Median: 73.01 vs FRA:BO1: 57.00

BioCryst Pharmaceuticals's Days Sales Outstanding declined from Mar. 2023 (66.19) to Mar. 2024 (57.72).


BioCryst Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for BioCryst Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Days Sales Outstanding Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.43 337.03 43.48 52.68 60.04

BioCryst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.19 59.12 58.10 54.60 57.72

Competitive Comparison of BioCryst Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Days Sales Outstanding falls into.



BioCryst Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

BioCryst Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (47.765 + 52.223) / 2 ) / 303.905*365
=49.994 / 303.905*365
=60.04

BioCryst Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding (Q: Mar. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )*Days in Period
=( (52.223 + 55.739) / 2 ) / 85.34*365 / 4
=53.981 / 85.34*365 / 4
=57.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals  (FRA:BO1) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


BioCryst Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (FRA:BO1) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals (FRA:BO1) Headlines

No Headlines